Загрузка...

Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats

Abaloparatide is a novel, potent and selective activator of parathyroid hormone receptor 1 (PTHR1) under clinical development for the treatment of osteoporosis. We assessed the effect of 6 weeks of abaloparatide on bone mass, microarchitecture, quality and strength in ovariectomized (OVX) rats. Afte...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Calcif Tissue Int
Главные авторы: Bahar, Hila, Gallacher, Kyla, Downall, Julie, Nelson, Carol A., Shomali, Maysoun, Hattersley, Gary
Формат: Artigo
Язык:Inglês
Опубликовано: Springer US 2016
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5055567/
https://ncbi.nlm.nih.gov/pubmed/27395059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00223-016-0171-1
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!